From owner-ageing@net.bio.net Fri Nov 01 22:00:00 1996 Path: biosci!MALTANET.OMNES.NET!mtroisi From: mtroisi@MALTANET.OMNES.NET (mtroisi) Newsgroups: bionet.molbio.ageing Subject: Web site(s) directory on ageing Date: 2 Nov 1996 01:55:07 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 11 Sender: daemon@net.bio.net Distribution: world Message-ID: <327BA968.223E@maltanet.omnes.net> NNTP-Posting-Host: net.bio.net Can anyone help me to get information on website(s) and news groups that deal with Ageing and Gerontological Research. This information is being requested to help us build a rather comprehensive research tool directory All forms of help will be appreciated. Thanks a million for your cooperation and collaboration Regards to all Prof.Joseph Troisi Institute of Gerontology Malta From owner-ageing@net.bio.net Sat Nov 02 22:00:00 1996 Path: biosci!internet!biosci!not-for-mail From: biohelp (BIOSCI Administrator) Newsgroups: bionet.molbio.ageing Subject: BIOSCI/bionet miniFAQ & Fundraiser Date: 3 Nov 1996 02:00:48 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 239 Sender: daemon@net.bio.net Distribution: world Message-ID: <199611031000.CAA29253@net.bio.net> NNTP-Posting-Host: net.bio.net (LAST REVISION: 30-JUL-95) This BIOSCI "miniFAQ" is designed to answer the questions that come up the *most frequently*. The main BIOSCI FAQ (Frequently Asked Questions) is accessible on the World Wide Web at URL http://www.bio.net/. If you can not find an answer to your question in this or other documentation, the BIOSCI technical support staff answers e-mail queries sent to biosci-help@net.bio.net We can only answer questions about the use of the newsgroups and mailing lists. We unfortunately do not have the staff to do Internet information searches or answer scientific questions. Please post those to the appropriate BIOSCI/bionet newsgroups. Contents: -------- 0) BIOSCI NEEDS YOUR SUPPORT!! 1) Using the WWW to access the BIOSCI/bionet newsgroups. 2) What to do about "spams," i.e., junk mail, ads, etc. 3) Examples of subscribing and unsubscribing to the mailing lists. 4) The BIOSCI user address and research interest directory. 0) BIOSCI NEEDS YOUR SUPPORT!! ------------------------------ BIOSCI's government funding has been expended, and we are now operating solely from advertising revenue that we have raised from our Web site at http://www.bio.net/. We need just a few minutes of your time to help us serve you. You can do two important things which will take very little time for you individually and will immensely help us continue to help you. First, please use our WWW system at http://www.bio.net/ to access the archives. You can post or reply to messages via your Web browser as described in item #1 below. Your usage helps attract sponsors. If you contact any of our sponsors, please be sure to thank them for supporting BIOSCI. It is critical for them to get this feedback if they are to continue their sponsorship for the long term. Second, if you work for a company or organization that provides products or services of interest to the biology community, please pass this message on to your marketing or marketing communications department or other appropriate group. Please ask them to help support BIOSCI by sponsoring our Web site and explain the uses and benefits of the system to the biology community. If they are interested, they can then contact us for further information at our tech support address, biosci-help@net.bio.net. 1) Using the WWW to access the BIOSCI/bionet newsgroups. -------------------------------------------------------- As of 10 December 1995, all BIOSCI/bionet full newsgroups are accessible through the World Wide Web (WWW) at URL http://www.bio.net. One can read and reply publicly or privately to both recent postings and archived messages through one's Web browser if it is configured properly to send e-mail. Each newsgroup is equipped with its own WAIS index. The main BIOSCI home page also has access to the BIO-JOURNALS Table of Contents database WAIS index and the BIOSCI user address database described in another item further below. 2) What to do about "spams," i.e., junk mail, ads, etc. ------------------------------------------------------- BIOSCI is a set of parallel USENET newsgroups (the "bionet" groups), mailing lists, and a hypermail archive at URL http://www.bio.net/. The same postings are distributed on all media (except for a small number of mailing-list-only groups at net.bio.net). Unfortunately it is becoming a despicable practice on the Internet (by a few people out to make a fast buck) to do automated mass postings to thousands of newsgroups and mailing lists. These attempts to grab free advertising are refered to as "spams" in the usual, somewhat boneheaded, net terminology. USENET is more susceptible to this practice, and many spams originate on the USENET groups and then are passed on to the mailing lists. However, spammers also get lists of mailing addresses and hit these too, so neither medium is immune. What should you do personally if you get junk mail? --------------------------------------------------- Just delete it and move on without reading it further. Filing a protest is becoming increasingly useless because spammers are often disguising the addresses where the messages are sent from. Unless you really understand Internet mail systems, your attempt at protest by sending replies to the message will often end up being sent to the address of an innocent person that the spammer is victimizing. What can BIOSCI/bionet do to protect its newsgroups? ---------------------------------------------------- The only solution currently available is to moderate the newsgroup. If this newsgroup is already moderated, then you are in good shape. Moderation protects the USENET distribution from about 95% of the spams that are being sent to date and protects the mailing lists completely. Moderation means, however, that someone has to take the time to review each message before it goes out. We have set up software here that simply allows the moderator to forward to an address at net.bio.net messages that (s)he wishes to have distributed. This takes no more time than that needed to read the message and pass it on, say about 1 min. per message. Most newsgroups currently have a discussion leader who is responsible for their newsgroup. The discussions leaders and their e-mail addresses are listed in the BIOSCI Information Sheet which is available on the Web at http://www.bio.net/. If a newsgroup is being hit with too many junk postings, please contact the discussion leader for that group and see if there is interest in moderating the group. Please do not assume that by simply posting a complaint to the newsgroup itself, anyone on the BIOSCI staff will act on your complaint. With close to 100 newsgroups to run, the BIOSCI staff has to rely on the discussion leaders of each newsgroup to report problems directly to us at biosci-help@net.bio.net. We will moderate any of our newsgroups if the discussion leader tells us that the readership of the group wishes to do so and if a moderator is willing to do the work. For most BIOSCI/bionet groups, this entails only a few minutes of work each day. Moderating a newsgroup will resolve probably 95% of the junk postings on the USENET distribution. Unfortunately there are easy ways for determined spammers to override the moderation mechanism on USENET, but we can protect our e-mail subscribers from unwanted postings if the newsgroup is moderated. You can also access our newsgroups over the WWW at URL http://www.bio.net. While this Web interface will not stop spammers from trying to post to the groups, this will give you yet another way, besides using USENET news, to keep the junk out of your personal mail files. For those of you with local USENET news systems, the Web interface will also give you faster access to new newsgroups and recent postings. 3) Examples of subscribing and unsubscribing to the mailing lists. ------------------------------------------------------------------ PLEASE NOTE: The BIOSCI management does NOT act on subscription/unsubscription requests that are posted improperly to the newsgroups and mailing lists. People who do this only bother everyone on the lists to no avail. Please be sure to follow the proper procedures below. Gory details are in the BIOSCI Information sheets on the Web at http://www.bio.net. Below we give an example utilizing the METHODS-AND-REAGENTS list at both of our two BIOSCI sites: Users in the Americas and Pacific Rim countries who use the BIOSCI ------------------------------------------------------------------ node at computer net.bio.net: ---------------------------- A) Determine the "listname" which is the <=8 character mail address ^^^^^^^^^^^^^ for the group. These can be found in the BIOSCI Info. Sheet. For the METHODS-AND-REAGENTS group the mailing address is methods@net.bio.net. The listname is the portion of the address to the left of the @ sign, i.e., "methods". The listname is used with the "subscribe" and "unsubscribe" commands illustrated below. B) Mail all commands in the body of a mail message addressed to biosci-server@net.bio.net. Do NOT send commands to the newsgroup posting addresses! Leave the Subject: line blank, any text on it will be ignored. C) In the body of your message put one or more of the following commands with an "end" command on the last line, e.g., subscribe methods unsubscribe methods end Do NOT put your e-mail address or other text on these lines. The server only allows you to cancel your subscription if the address on your mail header matches the address on our mailing list. Please ask for help at biosci-help@net.bio.net if your address has changed, e.g., if you know you are on the list but the server tells you that you are not a member. Users in Europe, Africa, and Central Asia who use the BIOSCI node at -------------------------------------------------------------------- computer daresbury.ac.uk (also known as dl.ac.uk): ------------------------------------------------- To subscribe and unsubscribe to/from the BIOSCI lists, you need to specify the full USENET newsgroup name with "bionet-news." prepended. The USENET newsgroup names are listed in the BIOSCI Information sheet on the Web at http://www.bio.net/. For the METHODS-AND-REAGENTS list the USENET newsgroup name is bionet.molbio.methds-reagnts, thus the appropriate commands are sub bionet-news.bionet.molbio.methds-reagnts unsub bionet-news.bionet.molbio.methds-reagnts These commands are included in a message addressed to mxt@dl.ac.uk, NOT to the newsgroup mailing addresses. As usual, include the text in the body of the message as text on the Subject: line is ignored. To unsubscribe from all the lists at the UK node, use unsub bionet-news Please note that if the address in the list is different than the one in your mail message header, you will not be able to unsubscribe by this method. If you have problems, please mail biosci@daresbury.ac.uk. 4) The BIOSCI user address and research interest directory. ----------------------------------------------------------- Please take this opportunity to add your name, address, and research interest information to the BIOSCI User Address Database if you have not already done so. You can fill out the address form directly through our Web page at URL http://www.bio.net/adrform.html. The address database is reindexed nightly for WWW access (the URL is http://www.bio.net/). If you are not directly on the Internet but can reach it by e-mail, please use our waismail server to access the user directory. waismail use is described above. You can also request a user address form by e-mail from biosci-help@net.bio.net. Please check your database entry from time-to-time to see if your address information is still up-to-date. Because of our limited personnel resources, we ask that you resubmit a *complete* form to revise your entry; we only replace complete entries and do not have resources to edit old forms. Sincerely, Dave Kristofferson BIOSCI/bionet Manager biosci-help@net.bio.net From owner-ageing@net.bio.net Sat Nov 02 22:00:00 1996 Path: biosci!bloom-beacon.mit.edu!news.mathworks.com!uunet!in3.uu.net!news-m01.ny.us.ibm.net!news-s01.ca.us.ibm.net!not-for-mail From: "Darryl R. Lum" Newsgroups: bionet.molbio.ageing,sci.med.nutrition,sci.med.pharmacy Subject: What is Pikamilone? Date: 3 Nov 1996 23:17:26 GMT Lines: 53 Message-ID: <01bbc9dd$6b94f460$86cb48a6@drlum> NNTP-Posting-Host: slip166-72-203-76.hi.us.ibm.net Mime-Version: 1.0 Content-Type: text/plain; charset=ISO-8859-1 Content-Transfer-Encoding: 7bit X-Newsreader: Microsoft Internet News 4.70.1155 Xref: biosci bionet.molbio.ageing:3029 sci.med.nutrition:52897 sci.med.pharmacy:35843 I recently received the following information on Pikamilone and would like feedback on the validity of the assertions. I have done a search on the internet Web and Usenet for "Pikamilone" and have found 0 hits. ---- BEGIN ASSERTIONS Pikamilone is an amazing powerful compound with antioxidant properties. It has been available in some parts of the world for over 25 years. Its primary use has been to both treat and combat brain ageing and associated disorders. At lower dosage, 50mg TID will achieve a tranquilizing effect. Increasing dosage to 100mg TID will bring about a stimulation effect and increase endurance. The effects of Pikamilone are felt quickly, most people will notice an impact within one hour. The body usually retains Pikamilone for up to six hours. Pikamilone crosses the blood brain barrier easily, which is why the results are normally experienced so rapidly. Pikamilone is a cleverly combined combination of GABA and Niacin, the way the two items are chemically bonded means the manufacturing process is formidable and that is why we have taken a great deal of both care and time in introduction of this exciting new product. Studies prove it to be more stimulating than Piracetam and to have a more pronounced effect than Vinpocetine. Other studies have shown Pikamilone has the ability to boost blood circulation, and blood supply to the brain, in a manner far superior to the results achieved with either Hydergine or Xanthinol Nicotinate. Toxicity is extremely low. LD50 is over 10 grams per kilo in mice. Pikamilone has shown no carcinogenic properties. ---- END ASSERTIONS There were 15 references to journal articles, but 14 of those references were from USSR journals and primarily from the late seventies to early eighties. Any information/opinions regarding Pikamilone are welcome! -- Darryl R. Lum drlum@ibm.net From owner-ageing@net.bio.net Sun Nov 03 22:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!news.sprintlink.net!news-peer.sprintlink.net!uunet!in3.uu.net!01-newsfeed.univie.ac.at!03-newsfeed.univie.ac.at!news.tuwien.ac.at!tubiomed From: igebes@fbma.tuwien.ac.at (Ille) Newsgroups: bionet.molbio.ageing Subject: Gerontechnology meeting ? Date: Mon, 04 Nov 96 11:00:00 GMT Organization: Vienna University of Technology, Austria Lines: 3 Message-ID: <55kibg$lqg_001@tuwien.ac.at> NNTP-Posting-Host: tubiomed.tuwien.ac.at X-Newsreader: News Xpress Version 1.0 Beta #4 Does anybody know about some Gerontechnology meeting, conference, etc. in 1997 ? Ille From owner-ageing@net.bio.net Sun Nov 03 22:00:00 1996 Path: biosci!daresbury!nntp-trd.UNINETT.no!nntp.uib.no!news From: Knut Jorgen Bjuland Newsgroups: bionet.molbio.ageing Subject: information about education Date: Mon, 04 Nov 1996 23:32:49 +0100 Organization: student.uib.no Lines: 6 Message-ID: <327E6F11.49E0@alfred.uib.no> Reply-To: stud1493@student.uib.no NNTP-Posting-Host: oppringt-18.uib.no Mime-Version: 1.0 Content-Type: text/plain; charset=iso-8859-1 Content-Transfer-Encoding: quoted-printable X-Mailer: Mozilla 3.0Gold (Win95; I) What is the best education to get into aging research. -- = Sign Knut J=F8rgen Bjuland From owner-ageing@net.bio.net Sun Nov 03 22:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!www.nntp.primenet.com!nntp.primenet.com!newspump.sol.net!news.mindspring.com!usenet From: lockshin@mindspring.com (Richard A. Lockshin) Newsgroups: bionet.molbio.ageing Subject: Re: Web site(s) directory on ageing Date: Mon, 04 Nov 1996 22:22:43 GMT Organization: MindSpring Enterprises, Inc. Lines: 21 Message-ID: <55lqhm$j92@camel0.mindspring.com> References: <327BA968.223E@maltanet.omnes.net> Reply-To: lockshin@mindspring.com NNTP-Posting-Host: ip193.an14.new-york4.ny.psi.net X-Server-Date: 4 Nov 1996 22:25:58 GMT X-Newsreader: Forte Free Agent 1.0.82 look for gerontological society of america (I don't have its address on hand right now, but it should be easy to find.) Also, apoptosis: http://rdz.stjohns.edu/~lockshin/index.html mtroisi@MALTANET.OMNES.NET (mtroisi) wrote: >Can anyone help me to get information on website(s) and news groups >that deal with Ageing and Gerontological Research. >This information is being requested to help us build a rather >comprehensive research tool directory >All forms of help will be appreciated. >Thanks a million for your cooperation and collaboration >Regards to all >Prof.Joseph Troisi >Institute of Gerontology >Malta Richard A. Lockshin (lockshin@mindspring.com;lockshin@sjumusic.stjohns.edu) From owner-ageing@net.bio.net Mon Nov 04 22:00:00 1996 Path: biosci!CS.Arizona.EDU!news.Arizona.EDU!hamblin.math.byu.edu!acs2.byu.edu!news.cuny.edu!news.sprintlink.net!news-pull.sprintlink.net!news.sprintlink.net!news-peer.sprintlink.net!howland.erols.net!cam-news-hub1.bbnplanet.com!news.bbnplanet.com!cpk-news-hub1.bbnplanet.com!cpk-news-feed1.bbnplanet.com!uky.edu!NewsWatcher!user From: sestus@aging.coa.uky.edu (Phyllis Wise) Newsgroups: bionet.molbio.ageing Subject: Assistant Professor Position Date: 5 Nov 1996 02:44:43 GMT Organization: University of Kentucky Lines: 30 Message-ID: NNTP-Posting-Host: 128.163.81.141 POSITION ANNOUNCEMENT ASSISTANT PROFESSOR MOLECULAR BIOLOGY OF AGING The Department of Physiology and the Sanders Brown Center on Aging at the University of Kentucky College of Medicine invite applications for a tenure-track position at the Assistant Professor level. We seek an individual who will establish a strong research program that emphasizes the use of molecular biological approaches to study age-related changes in physiological functions and who will participate in our teaching program. Special consideration will be given to candidates who complement existing strengths in the center on aging including the study of Alzheimer's disease and/or mechanisms of oxidative damage, neuron-glia interactions and/or neuronal plasticity. Candidates with training in other molecular and cellular aspects of aging will also be considered. Interactions with faculty within the College of Medicine, School of Biological Sciences, and the Markey Cancer Center provide a particularly stimulating research environment. Applicants must have a Ph.D. and/or M.D. degree and at least three years of postdoctoral experience. Interested individuals should send a curriculum vitae, a detailed statement of past experience, future research plans, and 3 letters of reference to: Dr. Phyllis M. Wise, Chair, Department of Physiology, College of Medicine, University of Kentucky, Lexington, KY 40536-0084. Review of applications will begin on December 20, 1996. Women and minority candidates are encouraged to apply. The University of Kentucky is an Affirmative Action/Equal Opportunity Employer. From owner-ageing@net.bio.net Tue Nov 05 22:00:00 1996 Path: biosci!biosci!not-for-mail From: David Stepp Newsgroups: bionet.biology.cardiovascular,bionet.metabolic-reg,bionet.molbio.ageing,bionet.molbio.evolution,bionet.molbio.proteins,bionet.molecules.peptides,bionet.neuroscience Subject: Physiologic Application of Molecular Biology Date: 5 Nov 1996 16:38:08 -0800 Organization: University of Wisconsin, Madison Lines: 24 Sender: biohelp@net.bio.net Distribution: world Message-ID: NNTP-Posting-Host: net.bio.net Xref: biosci bionet.biology.cardiovascular:1263 bionet.metabolic-reg:869 bionet.molbio.ageing:3035 bionet.molbio.evolution:5287 bionet.molbio.proteins:9202 bionet.molecules.peptides:494 bionet.neuroscience:16569 Many of us spend our days (and nights!) cloning, expressing and/or knocking out genes that interest us. Often times, however, we are too deep in the trees and lose sight of what our gene's function is in the context of a whole animal or even at the organ level. I would be interested to know what level of enthusiasm there is out there for studying the physiology of your favorite gene. If you are overexpressing a transcription factor that regulates cardiac gene expression, for example, what effect does this have on cardiac performance, blood pressure etc.? Granting agencies are asking for more than molecular biology these days; they want relevance to a physiological or pathophysiological process. Within this context, would you be interested in learning physiology techniques (blood pressure measurements, cardiac and smooth contractility, shear stress, electrophysiology etc) in a 2-3 week course as a means of broadening your knowledge base and enhancing your experimental research?? Please forward your thoughts and comments to jmiano@post.its.mcw.edu. Thanks in advance! Joe Miano & David W. Stepp From owner-ageing@net.bio.net Tue Nov 05 22:00:00 1996 Path: biosci!rutgers!news.sgi.com!news.mathworks.com!newsfeed.internetmci.com!news.fibr.net!news.world-net.net!alpha.comsource.net!news.cioe.com!cdial50 From: nataylor@hsonline.net (Noel A. Taylor) Newsgroups: bionet.molbio.ageing,sci.med.nutrition,sci.med.pharmacy Subject: Re: What is Pikamilone? Date: Wed, 06 Nov 96 02:00:03 GMT Organization: Hoosier Online Services Lines: 34 Message-ID: <327fe85a.0@news.hsonline.net> References: <01bbc9dd$6b94f460$86cb48a6@drlum> NNTP-Posting-Host: news.hsonline.net X-Newsreader: News Xpress Version 1.0 Beta #4 Xref: biosci bionet.molbio.ageing:3036 sci.med.nutrition:53000 sci.med.pharmacy:35946 In article <01bbc9dd$6b94f460$86cb48a6@drlum>, "Darryl R. Lum" wrote: >I recently received the following information on Pikamilone and would like >feedback on the validity of the assertions. > >I have done a search on the internet Web and Usenet for "Pikamilone" and >have found 0 hits. > >---- BEGIN ASSERTIONS > >Pikamilone is an amazing powerful compound with antioxidant properties. It >has been available in some parts of the world for over 25 years. > >Its primary use has been to both treat and combat brain ageing and >associated disorders. > >At lower dosage, 50mg TID will achieve a tranquilizing effect. > >Increasing dosage to 100mg TID will bring about a stimulation effect and >increase endurance. > >The effects of Pikamilone are felt quickly, most people will notice an >impact within one hour. > >The body usually retains Pikamilone for up to six hours. > >Pikamilone crosses the blood brain barrier easily, which is why the results >are normally experienced so rapidly. > >Pikamilone is a cleverly combined combination of GABA and Niacin Does it make your brain itch and turn purple polka dotted? --Noel From owner-ageing@net.bio.net Wed Nov 06 22:00:00 1996 Newsgroups: bionet.molbio.ageing Path: biosci!rutgers!news.sgi.com!www.nntp.primenet.com!nntp.primenet.com!dispatch.news.demon.net!demon!usenet2.news.uk.psi.net!uknet!usenet1.news.uk.psi.net!uknet!uknet!bcc.ac.uk!news From: Jim Subject: Pikamilon Sender: news@ucl.ac.uk (Usenet News System) Message-ID: <32822364.4444@pop-smtp.ich.ucl.ac.uk> Date: Thu, 7 Nov 1996 17:58:59 GMT Reply-To: sebcjdc@pop-smtp.ich.ucl.ac.uk Content-Transfer-Encoding: 7bit Content-Type: text/plain; charset=us-ascii Mime-Version: 1.0 X-Mailer: Mozilla 3.01Gold (Macintosh; I; 68K) Organization: UCL Lines: 3 Pikamilon is nicotinoyl-GABA (gamma amino butyric acid) Jim Clelland From owner-ageing@net.bio.net Wed Nov 06 22:00:00 1996 Path: biosci!agate!howland.erols.net!newsfeed.internetmci.com!btnet!netcom.net.uk!nntpfeed.doc.ic.ac.uk!sunsite.doc.ic.ac.uk!willow.cc.kcl.ac.uk!mail3.kcl.ac.uk!kgva1818 From: CONSTANTINOS PROUSKAS Newsgroups: bionet.molbio.ageing Subject: Re: Web site(s) directory on ageing Date: Thu, 7 Nov 1996 13:21:21 +0000 Organization: King's College London Lines: 68 Message-ID: References: <327BA968.223E@maltanet.omnes.net> NNTP-Posting-Host: mail3.kcl.ac.uk Mime-Version: 1.0 Content-Type: TEXT/PLAIN; charset=US-ASCII In-Reply-To: <327BA968.223E@maltanet.omnes.net> On 2 Nov 1996, mtroisi wrote: > Can anyone help me to get information on website(s) and news groups > that deal with Ageing and Gerontological Research. > This information is being requested to help us build a rather > comprehensive research tool directory > All forms of help will be appreciated. > Thanks a million for your cooperation and collaboration > Regards to all > Prof.Joseph Troisi > Institute of Gerontology > Malta > > > Dear Professor Joseph Troisi, My name is Constantinos Prouskas and I am studying an MPhil/PhD degree in Gerontology at King's College, London, Age Concern Institute of Gerontology. I have some information which was given to me by the Department and which may be of good use to you. The reference is: Susannah Tredwell,(1996) GRC NEWS, May, Page 7 and 11. The www addresses which I send you were taken from there. 1). Gerontology Research Centre: http://biblio.ucs.sfu.ca/gero/ 2). Joyce Post's list Internet and e-mail resources on aging: http://www.aoa.dhhs.gov/aoa/pages/jpostlst.html 3). ADEAR: http://www.cais.net/adear This is the web site Alzheimer's disease Educational and Referral Center 4). Aeiveos: http://www.aeiveos.com/ This is a Biotechnology Research and Education company "dedicated to understanding the causes of aging" 5). Canadian Medical Association: http://www.hwc.ca:8080/cma 6). Centre for Gerontology, University of Alberta: http://www.hwc.ca/datahpsb/seniors/crc/centre.html 7). Centre for Studies of Aging, University of Toronto: http://www.library.utoronto.ca/www/aging/depthome.html 8). DeathNET: http://www.rights.org/~deathnet/ DeathNet specialises on issues concerning death and dying like euthanasia, suicide, terminal diseases, palliative care etc 9). Health Canada: http://hpb1.hwc.ca/links/english.html 10). PharmInfo: http://pharminfocom/ 11). Seniors Computer Information Project: http://www.crm.mb.ca/scip/ 12). Seniors Directorate: http://hpb1.hwc.ca/datahpsb/seniors/senpage.html 13). Statistics Canada (http://www.statcan.ca/start.html 14). Third Age Centre, St.Thomas University: http://www.mbnet.mb.ca/crm/nb/advoc/3rdage1.html The above information should be useful to you and to other people interested in the field. I will come back to it if I get hold of any other addresses. Good Luck with your project, Best Regards, Constantinos Prouskas, Age Concern Institute Of Gerontology, King's College London, University Of London, United Kingdom From owner-ageing@net.bio.net Wed Nov 06 22:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!howland.erols.net!netnews.com!ix.netcom.com!news From: bellew@ix.netcom.com (Leo Bellew) Newsgroups: bionet.biology.cardiovascular,bionet.metabolic-reg,bionet.molbio.ageing,bionet.molbio.evolution,bionet.molbio.proteins,bionet.molecules.peptides,bionet.neuroscience Subject: Re: Physiologic Application of Molecular Biology Date: Thu, 07 Nov 1996 02:52:47 GMT Organization: Netcom Lines: 43 Message-ID: <32824be3.49540134@nntp.ix.netcom.com> References: Reply-To: bellew@ix.netcom.com NNTP-Posting-Host: phi-pa11-56.ix.netcom.com Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-NETCOM-Date: Wed Nov 06 6:56:03 PM PST 1996 X-Newsreader: Forte Agent .99f/32.299 Xref: biosci bionet.biology.cardiovascular:1267 bionet.metabolic-reg:870 bionet.molbio.ageing:3037 bionet.molbio.evolution:5290 bionet.molbio.proteins:9210 bionet.molecules.peptides:497 bionet.neuroscience:16596 I have been the architect or chief engineer on many high-tech computer software projects over the last 30 years where we have developed computer models of reality in many different situations utilizing engineering devices borrowed from areas such as artificial language and automata theory. I am very interested in the potential for utilizing these technologies in mapping the human genome to physiological function. In your note, you seem to imply that the relationships are known, at least in respect to the physiology techniques the course would be devoted to. Can you tell me if the problem of relating the human genome to physiological function is largely solved, and what formal mental, mathematical or simulative models provide the loci for that solution. Leo Bellew On 5 Nov 1996 16:38:08 -0800, David Stepp wrote: > >Many of us spend our days (and nights!) cloning, expressing and/or >knocking out genes that interest us. Often times, however, we are too >deep in the trees and lose sight of what our gene's function is in the >context of a whole animal or even at the organ level. I would be >interested to know what level of enthusiasm there is out there for >studying the physiology of your favorite gene. If you are overexpressing >a transcription factor that regulates cardiac gene expression, for >example, what effect does this have on cardiac performance, blood >pressure etc.? > >Granting agencies are asking for more than molecular biology these days; >they want relevance to a physiological or pathophysiological process. >Within this context, would you be interested in learning physiology >techniques (blood pressure measurements, cardiac and smooth contractility, >shear stress, electrophysiology etc) in a 2-3 week course as a means of >broadening your knowledge base and enhancing your experimental research?? > >Please forward your thoughts and comments to jmiano@post.its.mcw.edu. > >Thanks in advance! > > >Joe Miano & David W. Stepp From owner-ageing@net.bio.net Wed Nov 06 22:00:00 1996 Path: biosci!bcm.tmc.edu!news.msfc.nasa.gov!newsfeed.internetmci.com!in3.uu.net!news-m01.ny.us.ibm.net!news-s01.ca.us.ibm.net!not-for-mail From: "Darryl R. Lum" Newsgroups: bionet.molbio.ageing,sci.med.nutrition,sci.med.pharmacy Subject: Abstracts on Picamilon, Pikamilon, and Pikamilona but not Pikamilone Date: 7 Nov 1996 23:00:00 GMT Lines: 530 Message-ID: <01bbccff$a7458ae0$43cb48a6@drlum> NNTP-Posting-Host: slip166-72-203-67.hi.us.ibm.net Mime-Version: 1.0 Content-Type: text/plain; charset=ISO-8859-1 Content-Transfer-Encoding: 7bit X-Newsreader: Microsoft Internet News 4.70.1155 Xref: biosci bionet.molbio.ageing:3040 sci.med.nutrition:53073 sci.med.pharmacy:36064 I got a mailer from a nootropic supplier selling "Pikamilone". I did a Medline search from 1966 to 1996 and found references for "Picamilon", "Pikamilon" and "Pikamilona" but not "Pikamilone". "Pikamilona" is how the Russians spell it, and "Pikamilon" is how it is translated into English. It also is called Picamilon. (seems to me silly to change the spelling in translation but that's how medline did it). Also, the research Pikamilon(a) is "nicotinoyl-GABA" while the Pikamilone product is "a clever combination of NIACIN and GABA". I believe that NIACIN is not in any way a nicotinic receptor agonist. I do not know the technical relationship between Nicotinic receptors, "niconinoyl" preparations, "nicotine" as found in cigarettes, and whether Niacin has anything to do with it at all. I do know however that nicotine has cerebrovascular effects and alters cognition etc.. It seems to me that a Nicotine-Gaba preparation would be markedly different than a Niacin-GABA preparation, even though Niacin itself has its own vascular effects. If anyone has more information on Pikamilone, please relay! The research articles I found on Pikamilon(a) did >NOT< substantiate all the claims that they made for Pikamilone, however the research is interesting! ARTICLE TITLE: Effects of drugs on blood-brain barrier permeability in rats chronically intoxicated by ethanol. ARTICLE SOURCE: Ann Ist Super Sanita (Italy), 1990, 26(1) p39-42 AUTHOR(S): Borisenko SA AUTHOR'S ADDRESS: Department of Neuropharmacology, Academy of Medical Sciences, USSR, Moscow. MAJOR SUBJECT HEADING(S): Alcohol Deterrents [pharmacology]; Alcohol, Ethyl [toxicity]; Alcoholism [physiopathology]; Blood-Brain Barrier [drug effects] MINOR SUBJECT HEADING(S): Alcohol, Ethyl [pharmacology]; Disulfiram [pharmacology]; Dopa [metabolism]; Pinocytosis [drug effects]; Psychotropic Drugs [pharmacology]; Rats, Inbred Strains; Rats; Tryptophan [metabolism]; Tyrosine [metabolism] INDEXING CHECK TAG(S): Animal PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: Male Wistar rats were divided in free choice conditions into heavy-drinkers consuming greater than 3.5 g/kg of ethanol daily (HD), and light-drinkers consuming less than 2.0 g/kg/day (LD). Subsequent 30 day intragastric administration of 25% ethanol (8-11 g/kg/day) caused an increase in permeability of the BBB to 14C-tyrosine, 14C-tryptophan and 14C-DOPA at all the stages of alcoholization. At late stages of intoxication (20-30 days) the penetration of horseradish peroxidase (HRP) indicating pinocytosis was present. All the changes were more pronounced in LD than in HD rats. Disulfiram, and to a lesser extent phenazepam and diazepam, when repeatedly injected (for 16-30 days) together with ethanol aggravated its effects. Clonidine and haloperidol antagonized ethanol-induced increase of the BBB permeability to labelled compounds and HRP in the two groups of rats. Picamilon, lithium oxybutyrate, chlorpromazine and alpha-tocopherol had little effect on the penetration of radioactive tracers but effectively antagonized the penetration of HRP. The other drugs were without effects on the BBB regulatory and barrier functions altered by chronic alcoholization. In view of the BBB dysfunction in chronic alcoholics the adequacy of the above-mentioned drugs for their treatment is discussed. MEDLINE INDEXING DATE: 9012 ISSN: 0021-2571 LANGUAGE: English UNIQUE NLM IDENTIFIER: 90365369 CAS REGISTRY/EC NUMBER(S): 0 (Alcohol Deterrents); 55520-40-6 (Tyrosine); 63-84-3 (Dopa); 64-17-5 (Alcohol, Ethyl); 6912-86-3 (Tryptophan); 97-77-8 (Disulfiram) ARTICLE TITLE: [The characteristics of the retinal absorption of labelled preparations of pikamilon and GABA] VERNACULAR TITLE: [Osobennosti pogloshcheniia setchatkoi mechenykh preparatov pikamilona i GAMK.] ARTICLE SOURCE: Fiziol Zh (USSR), Mar-Apr 1991, 37(2) p116-8 AUTHOR(S): Logai IM; Leus NF; Rozanova ZA MAJOR SUBJECT HEADING(S): GABA [analogs & derivatives] [pharmacokinetics]; Retina [metabolism] MINOR SUBJECT HEADING(S): Absorption; Carbon Radioisotopes [diagnostic use]; Cattle; Dose-Response Relationship, Drug; Time Factors INDEXING CHECK TAG(S): Animal; Comparative Study; In Vitro CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: The velocity of absorption of GABA and its derivative picamilon carbon-labelled by isolated bovine retina has been studied. It is shown that maximal velocity of GABA and picamilon absorption falls at the second incubation minute, then it decreases. In all the cases the picamilon absorption velocity is higher than the GABA absorption velocity. With an increase of concentration in the incubation medium of the labeled preparation under study the absorption velocity of GABA remains practically unchanged, while that of picamilon slightly increases. MEDLINE INDEXING DATE: 9110 ISSN: 0201-8489 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 91276025 CAS REGISTRY/EC NUMBER(S): 0 (Carbon Radioisotopes); 34562-97-5 (nicotinoyl-GABA); 56-12-2 (GABA) ARTICLE TITLE: [Antihypoxic properties of GABA-containing vitamin derivatives] VERNACULAR TITLE: [Antigipoksicheskie svoistva GAMK-soderzhashchikh proizvodnykh vitaminov.] ARTICLE SOURCE: Farmakol Toksikol (USSR), Jan-Feb 1989, 52(1) p56-8 AUTHOR(S): Karaev AL; Kovler MA; Avakumov VM; Kopelevich VM; Bulanova LN MAJOR SUBJECT HEADING(S): Anoxia [drug therapy]; GABA [therapeutic use]; Vitamins [therapeutic use] MINOR SUBJECT HEADING(S): Anoxemia [chemically induced] [drug therapy]; Drug Screening; GABA [analogs & derivatives]; Mice; Nitroprusside; Pantothenic Acid [analogs & derivatives] [therapeutic use]; Pyridoxal Phosphate [analogs & derivatives] [therapeutic use] INDEXING CHECK TAG(S): Animal; Comparative Study; Male CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: The antihypoxic properties of GABA-containing vitamin derivatives (pyridoxalphosphate-GABA, picamilone, pantogam, sodium homopantothenate) as compared with GABA were studied. All agents were found to increase mouse life expectancy under hypoxia in contrast to GABA. MEDLINE INDEXING DATE: 8908 ISSN: 0014-8318 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 89211356 CAS REGISTRY/EC NUMBER(S): 0 (Vitamins); 15078-28-1 (Nitroprusside); 1977-33-9 (pantogab); 34562-97-5 (nicotinoyl-GABA); 54-47-7 (Pyridoxal Phosphate); 56-12-2 (GABA); 63221-68-1 (pyridoxal phosphate gamma-aminobutyric acid); 79-83-4 (Pantothenic Acid) ARTICLE TITLE: [The effect of antimigraine preparations on serotonin transport in the brain synaptosomes of rats] VERNACULAR TITLE: [Vliianie protivomigrenevykh preparatov na transport serotonina v sinaptosomakh mozga krys.] ARTICLE SOURCE: Farmakol Toksikol (USSR), Nov-Dec 1989, 52(6) p39-43 AUTHOR(S): Pukhal'skaia TG; Maisov NI; Mirzoian RS MAJOR SUBJECT HEADING(S): Anthranilic Acids [pharmacology]; Brain [drug effects]; Ergolines [pharmacology]; GABA [analogs & derivatives]; Methysergide [pharmacology]; Migraine [drug therapy]; Nicergoline [pharmacology]; Serotonin [metabolism]; Synaptosomes [drug effects] MINOR SUBJECT HEADING(S): Biological Transport [drug effects] [physiology]; Brain [metabolism]; Depression, Chemical; Dose-Response Relationship, Drug; GABA [pharmacology]; Rats, Inbred Strains; Rats; Synaptosomes [metabolism]; Tritium [diagnostic use] INDEXING CHECK TAG(S): Animal; Comparative Study; Male CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: Methisergide and nicergoline act as competitive inhibitors whereas tolfenamic acid as a non-competitive inhibitor of 3H-serotonin accumulation which occurs with the involvement of the high-affinity system of serotonin uptake by the rat brain synaptosomes. Methisergide, nicergoline and tolfenamic acid at concentrations ranging close to Ki value were found to enhance the basal and K(+)-induced release of 3H-serotonin from the rat brain synaptosomes. The findings obtained indicate the ability of the drugs to disturb serotonin transport. In addition, the drugs are likely to exert the depleting effect on serotonin stores in serotoninergic neurons. Picamilon failed to affect either the uptake or the release of serotonin from the rat brain synaptosomes. MEDLINE INDEXING DATE: 9006 ISSN: 0014-8318 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 90169075 CAS REGISTRY/EC NUMBER(S): 0 (Anthranilic Acids); 0 (Ergolines); 10028-17-8 (Tritium); 13710-19-5 (tolfenamic acid); 27848-84-6 (Nicergoline); 34562-97-5 (nicotinoyl-GABA); 361-37-5 (Methysergide); 50-67-9 (Serotonin); 56-12-2 (GABA) ARTICLE TITLE: [Results of the use of vasoactive preparation pikamilon in pigmented retinal abiotrophy] VERNACULAR TITLE: [Rezul'taty primeneniia vazoaktivnogo preparata pikamilona pri pigmentnoi abiotrofii setchatki.] ARTICLE SOURCE: Vestn Oftalmol (Russia), Jul-Sep 1995, 111(3) p20-2 AUTHOR(S): Davydova GA; Mukha AI MAJOR SUBJECT HEADING(S): GABA [analogs & derivatives]; Retinal Artery [drug effects]; Retinal Degeneration [drug therapy]; Vasodilator Agents [therapeutic use] MINOR SUBJECT HEADING(S): Adolescence; Adult; Aged; GABA [administration & dosage] [pharmacology] [therapeutic use]; Injections, Intramuscular; Middle Age; Retinitis Pigmentosa [drug therapy]; Solutions; Time Factors; Vasodilator Agents [administration & dosage] [pharmacology]; Visual Acuity; Visual Fields INDEXING CHECK TAG(S): Comparative Study; Female; Human; Male CITATION TYPE: English Abstract PUBLICATION TYPE: CLINICAL TRIAL; JOURNAL ARTICLE ABSTRACT: Eighty patients with pigmented retinal abiotrophy (PRA) and 20 controls were examined. The perfusion pressure and arteriovenous coefficient are markedly reduced in patients with stages 1-2 PRA, in comparison with controls. Deterioration of the visual function in patients with stages 3-4 PRA vs. that in stages 1-2 was associated with a more marked reduction of the hemodynamic parameters and the status of ocular vessels. Pikamilon therapy in a dose of 2 ml of 10% solution once a day intramuscularly for 10 days led to improvement of the visual function and ocular hemodynamics in patients with PRA. Treatment efficacy was higher in patients with disease stages 1-2. Pikamilon is recommended for the treatment of patients with PRA. MEDLINE INDEXING DATE: 9602 ISSN: 0042-465X LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 96046228 CAS REGISTRY/EC NUMBER(S): 0 (Solutions); 0 (Vasodilator Agents); 34562-97-5 (nicotinoyl-GABA); 56-12-2 (GABA) ARTICLE TITLE: [Lipid peroxidation markers in the exhaled breath and microsomal oxidation in patients with chronic diffuse liver diseases] VERNACULAR TITLE: [Markery perekisnogo okisleniia lipidov v vydykhaemom vozdukhe i mikrosomal'noe okislenie u bol'nykh s khronicheskimi diffuzionnymi bolezniami pecheni.] ARTICLE SOURCE: Ter Arkh (Russia), 1995, 67(4) p50-3 AUTHOR(S): Loginov AS; Bendikov EA; Petrakov AV MAJOR SUBJECT HEADING(S): Lipid Peroxidation; Liver Diseases [enzymology]; Microsomes, Liver [enzymology] MINOR SUBJECT HEADING(S): Adult; Antipyrine [analysis] [diagnostic use] [pharmacokinetics]; Biological Markers [analysis]; Breath Tests; Butanes [analysis]; Chronic Disease; Liver Diseases [diagnosis]; Middle Age; Molecular Weight; Pentanes [analysis]; Prognosis INDEXING CHECK TAG(S): Comparative Study; Female; Human; Male CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: Low-molecular hydrocarbons (butan, pentan) from the exhaled air as lipid peroxidation (LPO) markers were quantified in patients with chronic diffuse liver diseases. The study was also made of microsomal oxidation enzymic activity by antipirin metabolism. The above parameters were followed up in the course of antioxidant treatment. As shown by total butan and pentan levels, LPO activity varied with the disease, being high in hepatic cirrhosis and primary biliary cirrhosis, but low in chronic active hepatitis and fat dystrophy. Increased levels of butan and pentan occurred in association with inhibited activity of P450-dependent monooxygenases. This was determined by antipirin biotransformation and confirmed by a strong inverse correlation between the amount of hydrocarbons and antipirin metabolites (4-hydroxy- and norantipirin) clearance. In the course of antioxidant therapy the most pronounced inhibiting action on formation of low-molecular hydrocarbons was distinctive of essenciale, pikamilon and copmplivit. Relevant efficacy of carsil was weaker. Similar regularity for these drugs takes place in relation to activation of microsomal oxidation. MEDLINE INDEXING DATE: 9509 ISSN: 0040-3660 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 95304456 CAS REGISTRY/EC NUMBER(S): 0 (Biological Markers); 0 (Butanes); 0 (Pentanes); 106-97-8 (butane); 109-66-0 (pentane); 60-80-0 (Antipyrine) ARTICLE TITLE: [Results of pikamilon use in the treatment of patients with open-angle glaucoma] VERNACULAR TITLE: [Rezul'taty primeneniia pikamilona v lechenii bol'nykh otkrytougol'noi glaukomoi.] ARTICLE SOURCE: Vestn Oftalmol (Russia), Oct-Dec 1994, 110(4) p4-7 AUTHOR(S): Kolomoitseva EM; Ermakova VN; Abdulkadyrova MZh MAJOR SUBJECT HEADING(S): Analgesics [therapeutic use]; GABA [analogs & derivatives]; Glaucoma, Open-Angle [drug therapy] MINOR SUBJECT HEADING(S): Aged; Analgesics [administration & dosage]; GABA [administration & dosage] [therapeutic use]; Time Factors INDEXING CHECK TAG(S): Comparative Study; Female; Human; Male CITATION TYPE: English Abstract PUBLICATION TYPE: CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE ABSTRACT: Administration of pikamilon, a cerebrovascular and nootropic drug, to patients with primary open-angle glaucoma with normalized intraocular pressure and declining visual function resulted in improvement of the central and peripheral visual fields manifesting by improvement of individual sensitivity threshold, decreased area and intensity of scotomas; the treatment had a favorable effect on light sensitivity and vision acuity in some patients. No noticeable effect on arterial pressure was observed. The drug did not reduce the intraocular pressure. MEDLINE INDEXING DATE: 9506 ISSN: 0042-465X LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 95176463 CAS REGISTRY/EC NUMBER(S): 0 (Analgesics); 34562-97-5 (nicotinoyl-GABA); 56-12-2 (GABA) ARTICLE TITLE: [The effect of pikamilon and fenibut on the blood supply of the brain at rest and under gravitational exposures] VERNACULAR TITLE: [Vliianie pikamilona i fenibuta na krovosnabzhenie golovnogo mozga v usloviiakh pokoia i pri gravitatsionnykh vozdeistviiakh.] ARTICLE SOURCE: Eksp Klin Farmakol (Russia), Jan-Feb 1993, 56(1) p28-31 AUTHOR(S): Sapegin ID; Beketov AI MAJOR SUBJECT HEADING(S): Brain [blood supply] [drug effects]; GABA [analogs & derivatives]; Gravitation; Rest [physiology] MINOR SUBJECT HEADING(S): Brain [metabolism]; GABA [pharmacology]; Motion Sickness [physiopathology]; Oxygen Consumption [drug effects]; Partial Pressure; Posture; Rabbits INDEXING CHECK TAG(S): Animal; Comparative Study; Female; Male CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: The effects of Picamilonum, 10 mg/kg, and Phenibutum, 50 mg/kg, on the cerebral blood flow, oxygen saturation and vascular reactivity in the cerebral cortex, thalamus, and hypothalamus were studied at rest during antiorthostatic hypokinesia and while rocking in antiorthostasis. Picamilonum was shown to have more steady vasodilatory effect, but it decreased a cerebrovascular response to CO2 and O2 inhalation. The reactivity of cerebral vessels to antiorthostasis under the influence of the drugs inversed, that of cerebrovascular vessels to CO2 inhalation decreased. Picamilonum enhanced vasoconstrictory responses to CO2 inhalation, whereas Phenibutum decreased it. With the combined effects of Phenibutum and Picamilonum, while rocking in antiorthostasis, a phase of vasodilatation was not observed and oxygen saturation and cerebrovascular reactivity were decreased. MEDLINE INDEXING DATE: 9310 ISSN: 0869-2092 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 93313503 CAS REGISTRY/EC NUMBER(S): 1078-21-3 (4-amino-3-phenylbutyric acid); 34562-97-5 (nicotinoyl-GABA); 56-12-2 (GABA) ARTICLE TITLE: [Effect of psychotropic drugs on the structure and function of the adrenal glands of control and stressed animals] VERNACULAR TITLE: [Osobennosti vliianiia psikhotropnykh sredstv na strukturno-funktsional'noe sostoianie nadpochechnikov intaktnykh i stressirovannykh zhivotnykh.] ARTICLE SOURCE: Probl Endokrinol (Mosk) (USSR), May-Jun 1992, 38(3) p41-4 AUTHOR(S): Kresiun VI; Rozhkovskii Ia V MAJOR SUBJECT HEADING(S): Adrenal Glands [drug effects]; Psychotropic Drugs [pharmacology]; Stress [physiopathology] MINOR SUBJECT HEADING(S): Adrenal Glands [pathology] [physiopathology]; Ascorbic Acid [metabolism]; Chronic Disease; Hypertrophy [physiopathology]; Lipids [metabolism]; Phospholipids [metabolism]; Rats, Inbred Strains; Rats; Reference Values; Stress [pathology] INDEXING CHECK TAG(S): Animal; Male CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: The purpose of the experiment was to investigate the structure and function of the rat adrenal glands under chronic stress and its correction. Chronic stress is known to cause hypertrophy of the adrenals, enlargement of the area of nuclei and width of the cortical and medullary layers, a decrease in the content and pathological distribution of phospholipids, ascorbic acid and neutral lipids reflecting the function of these glands. Preventive courses of litonit, pikamilon and, to a lesser degree, piracetam and relanium weakened or removed characteristic pathomorphological changes in the adrenal structure. Complex analysis of the extracerebral mechanisms of each drug revealed the highest preventive activity of litonit which can be used to correct the adrenal glands under chronic stress. MEDLINE INDEXING DATE: 9212 ISSN: 0375-9660 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 92383170 CAS REGISTRY/EC NUMBER(S): 0 (Lipids); 0 (Phospholipids); 0 (Psychotropic Drugs); 50-81-7 (Ascorbic Acid) ARTICLE TITLE: [Pikamilon pharmacokinetics in animals] VERNACULAR TITLE: [Farmakokinetika pikamilona u zhivotnykh.] ARTICLE SOURCE: Farmakol Toksikol (USSR), Mar-Apr 1991, 54(2) p66-9 AUTHOR(S): Dorofeev BF; Kholodov LE MAJOR SUBJECT HEADING(S): Analgesics [pharmacokinetics]; GABA [analogs & derivatives] MINOR SUBJECT HEADING(S): Analgesics [administration & dosage] [analysis]; Biological Availability; Carbon Radioisotopes [diagnostic use]; Dose-Response Relationship, Drug; GABA [administration & dosage] [analysis] [pharmacokinetics]; Mice; Rats; Time Factors; Tissue Distribution INDEXING CHECK TAG(S): Animal CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: Pycamilon was shown to be rapidly absorbed in the blood (tmax = 0.23 h), to penetrate well through the blood-brain barrier and to be intensively uptaken by the animal organs and tissues and to be eliminated mainly in the urine (t1/2 = 0.51 h). The drug bioavailability at oral administration to mice is 21.9%, and to rats from 53 to 78.9% (according to the urinary excretion data). MEDLINE INDEXING DATE: 9112 ISSN: 0014-8318 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 91357158 CAS REGISTRY/EC NUMBER(S): 0 (Analgesics); 0 (Carbon Radioisotopes); 34562-97-5 (nicotinoyl-GABA); 56-12-2 (GABA) ARTICLE TITLE: [The characteristics of the retinal absorption of labelled preparations of pikamilon and GABA] VERNACULAR TITLE: [Osobennosti pogloshcheniia setchatkoi mechenykh preparatov pikamilona i GAMK.] ARTICLE SOURCE: Fiziol Zh (USSR), Mar-Apr 1991, 37(2) p116-8 AUTHOR(S): Logai IM; Leus NF; Rozanova ZA MAJOR SUBJECT HEADING(S): GABA [analogs & derivatives] [pharmacokinetics]; Retina [metabolism] MINOR SUBJECT HEADING(S): Absorption; Carbon Radioisotopes [diagnostic use]; Cattle; Dose-Response Relationship, Drug; Time Factors INDEXING CHECK TAG(S): Animal; Comparative Study; In Vitro CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: The velocity of absorption of GABA and its derivative picamilon carbon-labelled by isolated bovine retina has been studied. It is shown that maximal velocity of GABA and picamilon absorption falls at the second incubation minute, then it decreases. In all the cases the picamilon absorption velocity is higher than the GABA absorption velocity. With an increase of concentration in the incubation medium of the labeled preparation under study the absorption velocity of GABA remains practically unchanged, while that of picamilon slightly increases. MEDLINE INDEXING DATE: 9110 ISSN: 0201-8489 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 91276025 CAS REGISTRY/EC NUMBER(S): 0 (Carbon Radioisotopes); 34562-97-5 (nicotinoyl-GABA); 56-12-2 (GABA) ARTICLE TITLE: [Molecular mechanisms of the membrane-protective effect of litonit in chronic stress] VERNACULAR TITLE: [Molekuliarnye mekhanizmy membranoprotektornogo effekta litonita pri khronicheskom stresse.] ARTICLE SOURCE: Biull Eksp Biol Med (USSR), Jul 1990, 110(7) p63-5 AUTHOR(S): Kresiun VI; Rozhkovskii Ia V MAJOR SUBJECT HEADING(S): Nicotinic Acids [therapeutic use]; Stress [drug therapy]; Tranquilizing Agents [therapeutic use] MINOR SUBJECT HEADING(S): Antioxidants [metabolism]; Cell Membrane [drug effects]; Chronic Disease; Erythrocyte Membrane [drug effects]; Hypercholesterolemia [etiology] [prevention & control]; Nicotinic Acids [administration & dosage]; Rats, Inbred Strains; Rats; Stress [complications] [metabolism]; Time Factors; Tranquilizing Agents [administration & dosage] INDEXING CHECK TAG(S): Animal; Comparative Study; Male CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: It is confirmed that prophylactic use of Pyracetam (500 mg/kg), Pikamilon (10 mg/kg) and new product of GABA B-44 (30 mg/kg) for 10-days in the conditions of chronic stress normalizes the activity of the key enzymes of antiradical defence and the content of lipid peroxides, warns the decrement of phospholipids and the changes in its qualitative ratio, prevents multidirectional changes in the activity of ferments-markers in the membrane of the brain and erythrocytes. It is concluded that nootropic agents give membrane stabilizing effects. MEDLINE INDEXING DATE: 9102 ISSN: 0365-9615 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 91028208 CAS REGISTRY/EC NUMBER(S): 0 (Antioxidants); 0 (Nicotinic Acids); 0 (Tranquilizing Agents); 88161-48-2 (litonit) ARTICLE TITLE: [Comparative study of the effect of picamilone and piracetam on learning in rats in a radial maze] VERNACULAR TITLE: [Sravnitel'noe izuchenie vliianiia pikamilona i piratsetama na obuchenie krys v radial'nom labirinte.] ARTICLE SOURCE: Farmakol Toksikol (USSR), Jul-Aug 1989, 52(4) p14-7 AUTHOR(S): Voznesenskii AG; Kovalev GV; Sazhin VA MAJOR SUBJECT HEADING(S): GABA [analogs & derivatives]; Learning [drug effects]; Piracetam [pharmacology]; Pyrrolidinones [pharmacology] MINOR SUBJECT HEADING(S): GABA [pharmacology]; Memory, Short-Term [drug effects]; Memory [drug effects]; Rats INDEXING CHECK TAG(S): Animal; Comparative Study; Male CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: During four weeks rats were learned to visit consequently 4 baited arms in the 8-armed radial maze. Picamilone (nicotinoyl-GABA) in a dose of 10 mg/kg daily accelerated rats to reach 80% level of learning (to 20-28 trials). After picamilone injections rats obtained the maximal level of short-term memory as just 3-5 trials. Piracetam in a dose of 200 mg/kg daily exerted no effects on long-term and short-term memory of rats in the radial maze. MEDLINE INDEXING DATE: 9002 ISSN: 0014-8318 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 90033254 CAS REGISTRY/EC NUMBER(S): 0 (Pyrrolidinones); 34562-97-5 (nicotinoyl-GABA); 56-12-2 (GABA); 7491-74-9 (Piracetam) ARTICLE TITLE: [Effect of pikamilon on the cortical blood supply and microcirculation in the pial arteriole system] VERNACULAR TITLE: [Vliianie pikamilona na krovosnabzhenie kory i mikrotsirkuliatsiiu v sisteme pial'nykh arteriol.] ARTICLE SOURCE: Biull Eksp Biol Med (USSR), May 1989, 107(5) p581-2 AUTHOR(S): Mirzoian RS; Gan'shina TS; Kosoi MIu; Aleksandrin VV; Aleksandrin PN MAJOR SUBJECT HEADING(S): Cerebral Cortex [drug effects]; GABA [analogs & derivatives]; Pia Mater [drug effects] MINOR SUBJECT HEADING(S): Arterioles [drug effects]; Cerebral Cortex [blood supply]; Electrodes, Implanted; GABA [pharmacology]; Pia Mater [blood supply]; Rabbits; Rats; Time Factors; Vasodilation [drug effects] INDEXING CHECK TAG(S): Animal; Comparative Study; Male CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: Pikamilon was shown to increase blood supply in cerebral cortex in conscious rats and rabbits. The increase in blood flow has been revealed under intravenous, intraperitoneal and systemic administration of the drug. There is a pronounced dilatation of pial arterioles under pikamilon action while applied locally. Most dilation occurs in arterioles with the initial diameter of 10-20 microns. With the increase of pial arterioles diameter, dilatory effect of pikamilon, is reduced. MEDLINE INDEXING DATE: 8910 ISSN: 0365-9615 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 89287466 CAS REGISTRY/EC NUMBER(S): 34562-97-5 (nicotinoyl-GABA); 56-12-2 (GABA) ARTICLE TITLE: [The new cerebrovascular preparation pikamilon] VERNACULAR TITLE: [Novyi tserebrovaskuliarnyi preparat pikamilon.] ARTICLE SOURCE: Farmakol Toksikol (USSR), Jan-Feb 1989, 52(1) p23-6 AUTHOR(S): Mirzoian RS; Gan'shina TS MAJOR SUBJECT HEADING(S): Cerebrovascular Circulation [drug effects]; GABA [analogs & derivatives] MINOR SUBJECT HEADING(S): Cats; Cerebral Ischemia, Transient [drug therapy] [etiology] [physiopathology]; Cerebrovascular Disorders [chemically induced] [drug therapy] [physiopathology]; Drug Screening; Electrocardiography; GABA [pharmacology] [therapeutic use]; Hemodynamics [drug effects]; Serotonin [pharmacology]; Wakefulness [drug effects] [physiology]; Xenon Radioisotopes [diagnostic use] INDEXING CHECK TAG(S): Animal; Comparative Study CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE ABSTRACT: Picamilon, a sodium salt of N-nicotinoyl-gamma-aminobutyric acid, was shown to induce a significant increase of cerebral blood flow in conscious cats. Picamilon was found to inhibit neurogenic spasms of cerebral vessels that was followed by suppression of tonic activity and reflectory discharges in sympathetic nerves. Picamilon led to restoration of the initial condition of cerebral hemodynamics disturbed by a previous administration of serotonin. MEDLINE INDEXING DATE: 8908 ISSN: 0014-8318 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 89211344 CAS REGISTRY/EC NUMBER(S): 0 (Xenon Radioisotopes); 50-67-9 (Serotonin); 56-12-2 (GABA) ARTICLE TITLE: [Use of pikamilon in the combined treatment of patients with cerebral circulatory disorders] VERNACULAR TITLE: [Primenenie pikamilona v kompleksnom lechenii bol'nykh s rasstroistvami mozgovogo krovoobrashcheniia.] ARTICLE SOURCE: Vrach Delo (USSR), Dec 1988, (12) p18-9 AUTHOR(S): Zinchenko VA; Popov EA; Kalinichev SN; Lobzhanidze PV MAJOR SUBJECT HEADING(S): Cerebrovascular Disorders [drug therapy]; GABA [therapeutic use]; Nicotinic Acids [therapeutic use] MINOR SUBJECT HEADING(S): Adult; Aged; Brain [drug effects] [physiopathology]; Cerebrovascular Disorders [physiopathology] [psychology]; Combined Modality Therapy; Drug Combinations; Drug Evaluation; Middle Age; Psychophysiology; Tablets INDEXING CHECK TAG(S): Comparative Study; Human CITATION TYPE: English Abstract PUBLICATION TYPE: JOURNAL ARTICLE MEDLINE INDEXING DATE: 8908 ISSN: 0049-6804 LANGUAGE: Russian UNIQUE NLM IDENTIFIER: 89224243 CAS REGISTRY/EC NUMBER(S): 0 (Drug Combinations); 0 (Nicotinic Acids); 0 (Tablets); 56-12-2 (GABA) Darryl R. Lum mailto:drlum@ibm.net From owner-ageing@net.bio.net Thu Nov 07 22:00:00 1996 Newsgroups: bionet.molbio.ageing,sci.med.nutrition,sci.med.pharmacy From: nataylor@hsonline.net (Noel A. Taylor) Subject: Re: Abstracts on Picamilon, Pikamilon, and Pikamilona but not Pikamilone Organization: Hoosier Online Services References: <01bbccff$a7458ae0$43cb48a6@drlum> X-Newsreader: News Xpress Version 1.0 Beta #4 Date: Fri, 08 Nov 96 09:36:07 GMT NNTP-Posting-Host: cdial18.hsonline.net Message-ID: <3282f659.0@news.hsonline.net> Lines: 13 Path: biosci!agate!newsgate.cuhk.edu.hk!hammer.uoregon.edu!csulb.edu!news.sgi.com!su-news-hub1.bbnplanet.com!news.bbnplanet.com!cpk-news-hub1.bbnplanet.com!newsfeed.internetmci.com!news.fibr.net!news.world-net.net!alpha.comsource.net!news.cioe.com!news.hsonline.net!cdial18 Xref: biosci bionet.molbio.ageing:3041 sci.med.nutrition:53111 sci.med.pharmacy:36099 >Also, the research Pikamilon(a) is "nicotinoyl-GABA" while the Pikamilone >product is "a clever combination of NIACIN and GABA". I believe that >NIACIN is not in any way a nicotinic receptor agonist. I do not know the >technical relationship between Nicotinic receptors, "niconinoyl" >preparations, "nicotine" as found in cigarettes, and whether Niacin has >anything to do with it at all. I do know however that nicotine has >cerebrovascular effects and alters cognition etc.. It seems to me that a >Nicotine-Gaba preparation would be markedly different than a Niacin-GABA >preparation, even though Niacin itself has its own vascular effects. Niacin (Vitamin B3) is also known as nicotinic acid. --Noel From owner-ageing@net.bio.net Fri Nov 08 22:00:00 1996 Path: biosci!gavrilov.genebee.msu.su!leonid From: leonid@gavrilov.genebee.msu.su ("Leonid A.Gavrilov") Newsgroups: bionet.molbio.ageing Subject: Christmas story on aging and longevity Date: 9 Nov 1996 14:31:37 -0800 Organization: A.N.Belozersky Institute Lines: 78 Sender: daemon@net.bio.net Distribution: world Message-ID: NNTP-Posting-Host: net.bio.net Dear Colleagues, Recently we have received an international award for organizing the joint U.S.-Russian scientific workshop on mechanisms of aging and human longevity at Gerontology Research Center, Baltimore on December 7-20, 1996. We would like to use this lucky chance and to visit some other gerontological centers in USA after the workshop, to present our new scientific results and to discuss the opportunities for scientific collaboration. We already have positive experience with our seminars in USA during the visit in 1993 when the seminars were given at Detroit (The Wayne University), Baltimore (Gerontology Research Center), Fort Worth (University of North Texas Health Science Center at Fort Worth), Hyattsville (National Center for Health Statistics, Centers for Disease Control), Davis (University of California, Davis), Michigan (Barros Research Institute), Palo Alto (Stanford University School of Medicine) and many other places. Recommendations for our seminars could be obtained from: Dr.Robert Arking, Professor of Biological Sciences at Wayne State University, Detroit. Telephone: 313-577-2873. Dr. Donald Ingram, Research Psychologist within the Molecular Physiology and Genetics Section of the GRC. Telephone: 410-558-8178. Dr. Robert W.Gracy, Associate Dean for Research and Biotechnology. Texas College of Osteopathic Medicine, Graduate School of Biomedical Science. 3500 Camp Bowie Blvd., Fort Worth, TX 76107-2699. Telephone: 817-735-5400. The seminars are based on our book: THE BIOLOGY OF LIFE SPAN: A QUANTITATIVE APPROACH that was published in USA by Harwood Academic Publishers and has received more than 20 positive reviews in the most prestigeous scientific journals. Some more recent results used in our seminars are published in the following journals: 1. "Parental Age at Reproduction and Offspring Longevity", Reviews in Clinical Gerontology, 1996, vol.6, No.4 (In Press). 2. "A Typical Interdisciplinary Topic: Questions of the Mortality Dynamics", Archives of Gerontology and Geriatrics, 1995, vol.20, No.3, pp.283-293. 3. "Sex and Longevity", Nature, 1994, vol.367, No.6463,p.520. 4. "Fruit Fly Aging and Mortality", Science, 1993, vol.260, No.5114, p.1565. In the case if you are interested in our seminars, please let us know. Our CVs are available upon the request. Sincerely yours, Dr.Leonid A.Gavrilov, Ph.D. Principal Research Scientist A.N.Belozersky Institute Moscow State University 119899 Moscow, Russia FAX: 7-095-939-0338 7-095-939-3181 Email: leonid@gavrilov.genebee.msu.su Reserve email: gavrilov@glas.apc.org Dr.Natalia S.Gavrilova, Ph.D. Institute for Systems Analysis, Lab.10-2 Russian Academy of Sciences 9, 60-Let Oktyabrya 117312 Moscow, Russia Tel.: 7-095-427-0047 Fax: 7-095-939-3181 E-mail: natalia@gavrilov.genebee.msu.su gavrilov@glas.apc.org From owner-ageing@net.bio.net Mon Nov 11 22:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!www.nntp.primenet.com!nntp.primenet.com!feed1.news.erols.com!uunet!in2.uu.net!01-newsfeed.univie.ac.at!03-newsfeed.univie.ac.at!news.tuwien.ac.at!tubiomed From: igebes@fbma.tuwien.ac.at (Ille) Newsgroups: bionet.molbio.ageing Subject: Gerontechnology conference - when ? Date: Tue, 12 Nov 96 10:35:25 GMT Organization: Vienna University of Technology, Austria Lines: 5 Message-ID: <569jtd$akk_001@tuwien.ac.at> NNTP-Posting-Host: tubiomed.tuwien.ac.at X-Newsreader: News Xpress Version 1.0 Beta #4 Can anybody tell me whether (and if where and when) there is some conference, workshop, etc. on Gerontechnology in 1997 ? Thanks in advance, Ille From owner-ageing@net.bio.net Tue Nov 12 22:00:00 1996 Newsgroups: bionet.molbio.ageing Path: biosci!rutgers!uwm.edu!www.nntp.primenet.com!nntp.primenet.com!feed1.news.erols.com!howland.erols.net!newsfeed.internetmci.com!malgudi.oar.net!utnetw!mabrini From: mabrini@uoft03.utoledo.edu (Pan Parag) Subject: Look here! Message-ID: Sender: news@utnetw.utoledo.edu (News Manager) X-Newsreader: TIN [version 1.2 PL2] Date: Tue, 12 Nov 1996 22:35:25 GMT Lines: 15 I am looking for anybody who is a practicing biologist or a biology research professional who can grant me a 15 minute interview preferably over the phone. I am doing this as part of my assignment for my Biology class so that I can graduate. If anybody is willing to help me out, please respond with your name and phone number to the following e-mail address: mabrini@uoft03.utoledo.edu. If my paper is successful, I will send you a copy of it in the mail. Mark Abrinica University of Toledo 419-472-2999 From owner-ageing@net.bio.net Tue Nov 12 22:00:00 1996 Path: biosci!NMT.EDU!ccliff From: ccliff@NMT.EDU (Carter Cliff) Newsgroups: bionet.molbio.ageing Subject: A student needs advice... Date: 13 Nov 1996 11:29:06 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 15 Sender: daemon@net.bio.net Distribution: world Message-ID: <328A2167.41C67EA6@nmt.edu> NNTP-Posting-Host: net.bio.net I am an undergraduate at New Mexico Tech,studying Biology and Chemistry. My scientific interests center around the Molecular Biology of Ageing in Humans, and in development of gene therapies designed to slow ageing. I plan on attending graduate school, possibly medical shool, after graduation in the spring of 1998, and I would like some advice. > What schools are involved in molecular ageing research? Who are the professors involved in the research? > Are there any internships available in molecular ageing research labs? How do I apply? > What sorts of qualifications are companies/research-teams involved in ageing research and the development of anti-aging therapies looking for when they hire a new research scientist? Thankyou for your time. Carter Cliff From owner-ageing@net.bio.net Wed Nov 13 22:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!news.sprintlink.net!news-peer.sprintlink.net!news.hooked.net!usenet From: rag@hooked.net (Richard A. Goodman) Newsgroups: bionet.molbio.ageing,sci.med.nutrition,sci.med.pharmacy Subject: Re: What is Pikamilone? Date: Wed, 13 Nov 1996 23:57:38 GMT Organization: Hooked Online Services Lines: 72 Message-ID: <56dnii$rh2@its.hooked.net> References: <01bbc9dd$6b94f460$86cb48a6@drlum> Reply-To: rag@hooked.net NNTP-Posting-Host: webe-55.ppp.hooked.net X-Newsreader: Forte Free Agent 1.0.82 Xref: biosci bionet.molbio.ageing:3048 sci.med.nutrition:53395 sci.med.pharmacy:36506 "Darryl R. Lum" wrote: >I recently received the following information on Pikamilone and would like >feedback on the validity of the assertions. >I have done a search on the internet Web and Usenet for "Pikamilone" and >have found 0 hits. >---- BEGIN ASSERTIONS >Pikamilone is an amazing powerful compound with antioxidant properties. It >has been available in some parts of the world for over 25 years. >Its primary use has been to both treat and combat brain ageing and >associated disorders. >At lower dosage, 50mg TID will achieve a tranquilizing effect. >Increasing dosage to 100mg TID will bring about a stimulation effect and >increase endurance. >The effects of Pikamilone are felt quickly, most people will notice an >impact within one hour. >The body usually retains Pikamilone for up to six hours. >Pikamilone crosses the blood brain barrier easily, which is why the results >are normally experienced so rapidly. >Pikamilone is a cleverly combined combination of GABA and Niacin, the way >the two items are chemically bonded means the manufacturing process is >formidable and that is why we have taken a great deal of both care and time >in introduction of this exciting new product. >Studies prove it to be more stimulating than Piracetam and to have a more >pronounced effect than Vinpocetine. Other studies have shown Pikamilone >has the ability to boost blood circulation, and blood supply to the brain, >in a manner far superior to the results achieved with either Hydergine or >Xanthinol Nicotinate. >Toxicity is extremely low. LD50 is over 10 grams per kilo in mice. >Pikamilone has shown no carcinogenic properties. >---- END ASSERTIONS >There were 15 references to journal articles, but 14 of those references >were from USSR journals and primarily from the late seventies to early >eighties. >Any information/opinions regarding Pikamilone are welcome! >-- >Darryl R. Lum >drlum@ibm.net Darryl, I'd be real careful about this product. Some warning flags I see are the assertion that Pikamilone is a "cleverly combined combination", the assertion that they have taken a great deal of care and time in introducing the product, calling the manufacturing process "formidable," and calling it an "exciting new product." Doesn't excite me. And the logical connection between taking care and time in introducing a new product and it's having a "formidable" manufacturing process just doesn't follow. Sounds like PR hype. Rich G. From owner-ageing@net.bio.net Wed Nov 13 22:00:00 1996 Path: biosci!rutgers!uwm.edu!cs.utexas.edu!www.nntp.primenet.com!nntp.primenet.com!news.bbnplanet.com!cpk-news-hub1.bbnplanet.com!cpk-news-feed4.bbnplanet.com!maze.dpo.uab.edu!juniper.cis.uab.edu!news.lsu.edu!news.LaTech.edu!news.ttu.edu!news.tamu.edu!news From: "Dawn C." Newsgroups: bionet.molbio.ageing Subject: Re: A student needs advice... Date: Wed, 13 Nov 1996 17:04:22 -0600 Organization: Texas A&M University, College of Medicine Lines: 2 Message-ID: <328A53F6.177A@bigfoot.com> References: <328A2167.41C67EA6@nmt.edu> NNTP-Posting-Host: ppp12-09.rns.tamu.edu Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 3.0 (Win95; I) To: Carter Cliff Try UCSF, Dr. Elizabeth Blackburn. She works on Telomerase. From owner-ageing@net.bio.net Wed Nov 13 22:00:00 1996 Path: biosci!rutgers!uwm.edu!cs.utexas.edu!www.nntp.primenet.com!nntp.primenet.com!news.bbnplanet.com!cpk-news-hub1.bbnplanet.com!cpk-news-feed4.bbnplanet.com!maze.dpo.uab.edu!juniper.cis.uab.edu!news.lsu.edu!news.LaTech.edu!news.ttu.edu!news.tamu.edu!news From: "Dawn C." Newsgroups: bionet.molbio.ageing Subject: Re: Look here! Date: Wed, 13 Nov 1996 17:05:59 -0600 Organization: Texas A&M University, College of Medicine Lines: 2 Message-ID: <328A5457.76F1@bigfoot.com> References: NNTP-Posting-Host: ppp12-09.rns.tamu.edu Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 3.0 (Win95; I) I'm a doctoral student in Medical Biochemistry and Genetics with a published thesis on aging. What will the interview address? From owner-ageing@net.bio.net Wed Nov 13 22:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!howland.erols.net!portc02.blue.aol.com!portc01.blue.aol.com!audrey01.news.aol.com!not-for-mail From: kloewenth@aol.com Newsgroups: bionet.molbio.ageing Subject: Life Expectancy VS Puberty, need info. Date: 14 Nov 1996 04:50:29 GMT Organization: AOL http://www.aol.com Lines: 11 Sender: news@aol.com Message-ID: <19961114045300.XAA13029@ladder01.news.aol.com> NNTP-Posting-Host: ladder01.news.aol.com Does anyone know where I can find a Life Expectancy table that lists Life Expectancy versus age at which Puberty was reached? As I understand it, there is a theory that people that reach puberty later in life generally live longer. Is this true? Does anyone have any good references to this subject? If anyone has any leads I would greatly appreciate hearing from you or seeing a post. Thanks. KLoewenth@aol.com From owner-ageing@net.bio.net Thu Nov 14 22:00:00 1996 Path: biosci!APOPNET.COM!webmaster From: webmaster@APOPNET.COM (APOPTOSIS Online) Newsgroups: bionet.molbio.ageing Subject: APOPTOSIS Online Site Announcement Date: 14 Nov 1996 17:16:59 -0800 Organization: ApopNet Lines: 21 Sender: daemon@net.bio.net Distribution: world Message-ID: <328BD26B.398@apopnet.com> NNTP-Posting-Host: net.bio.net ApopNet has established a new web site "APOPTOSIS Online: The Apoptosis Information and Communication Center". You will find "APOPTOSIS Online" on the web at: http://www.apopnet.com "APOPTOSIS Online" features an online discussion board, a resume/position depository and a content-based resource center focusing on apoptosis-related information. Access to APOPTOSIS Online is entirely free, requiring only a simple one-time member registration. I hope you find "APOPTOSIS Online" an informative and valuable resource. Webmaster, APOPTOSIS Online From owner-ageing@net.bio.net Thu Nov 14 22:00:00 1996 Path: biosci!gavrilov.genebee.msu.su!leonid From: leonid@gavrilov.genebee.msu.su ("Leonid A.Gavrilov") Newsgroups: bionet.molbio.ageing Subject: Fortcoming seminars in USA, December 7 - January 15+++ Date: 15 Nov 1996 06:05:25 -0800 Organization: A.N.Belozersky Institute Lines: 110 Sender: daemon@net.bio.net Distribution: world Message-ID: NNTP-Posting-Host: net.bio.net To Whom It May Concern: The purpose of this message is to inform about our forthcoming visit with lectures and seminars in USA for the period of December 7, 1996 - January 15, 1997 (and perhaps later) and about our interest to develop broad U.S.-Russian collaboration including joint research projects. Recently we have received an international award for organizing the joint U.S.-Russian scientific workshop on mechanisms of aging and human longevity at Gerontology Research Center, Baltimore on December 7-20, 1996. The purpose of our forthcoming scientific mission in USA is to develop joint research projects on mechanisms of aging and longevity and to submit them for funding. We would like to use this lucky chance and to visit some other gerontological, biological and demographic centers in USA after the workshop, to present our new scientific results and to discuss the opportunities for scientific collaboration. We already have positive experience with our seminars in USA during the visit in 1993 when the seminars were given at Detroit (The Wayne University), Baltimore (Gerontology Research Center), Fort Worth (University of North Texas Health Science Center at Fort Worth), Hyattsville (National Center for Health Statistics, Centers for Disease Control), Davis (University of California, Davis), Michigan (Barros Research Institute), Palo Alto (Stanford University School of Medicine) and many other places. Recommendations for our seminars could be obtained from: - Dr.James Carey, University of California, Davis, Phone: 916-752-0475. - Dr.Robert Arking, Professor of Biological Sciences at Wayne State University, Detroit. Telephone: 313-577-2873. - Dr. Donald Ingram, Research Psychologist within the Molecular Physiology and Genetics Section of the Gerontology Research Center, NIA, Baltimore. Telephone: 410-558-8178. - Dr. Robert W.Gracy, Associate Dean for Research and Biotechnology. Texas College of Osteopathic Medicine, Graduate School of Biomedical Science. 3500 Camp Bowie Blvd., Fort Worth, TX 76107-2699. Telephone: 817-735-5400. - Dr.Joan F.Van Nostrand, National Center for Health Statistics Coordinator of data on aging, National Center for Health Statistics, Centers for Disease Control, Public Health Service, Hyattsville, Phone: 301-436-7104. - Prof. Barnett Rosenberg, Director of the Barros Research Institute, Holt, Michigan, Phone: 517-694-4788. The seminars are based on our book: THE BIOLOGY OF LIFE SPAN: A QUANTITATIVE APPROACH that was published in USA by Harwood Academic Publishers and has received more than 20 positive reviews in the international scientific journals. Some more recent results used in our seminars are partially published in the following journals: 1. "Parental Age at Reproduction and Offspring Longevity", Reviews in Clinical Gerontology, 1996, vol.6, No.4 (In Press). 2. "A Typical Interdisciplinary Topic: Questions of the Mortality Dynamics", Archives of Gerontology and Geriatrics, 1995, vol.20, No.3, pp.283-293. 3. "Sex and Longevity", Nature, 1994, vol.367, No.6463,p.520. 4. "Fruit Fly Aging and Mortality", Science, 1993, vol.260, No.5114, p.1565. In the case if you are interested in our seminars, please let us know. Our CVs are available upon the request. Sincerely yours, Dr.Leonid A.Gavrilov, Ph.D. Principal Research Scientist A.N.Belozersky Institute Moscow State University 119899 Moscow, Russia FAX: 7-095-939-0338 7-095-939-3181 Email: leonid@gavrilov.genebee.msu.su Reserve email: gavrilov@glas.apc.org Dr.Natalia S.Gavrilova, Ph.D. Institute for Systems Analysis, Lab.10-2 Russian Academy of Sciences 117312 Moscow, Russia Tel.: 7-095-427-0047 E-mail: natalia@gavrilov.genebee.msu.su P.S.: Our contact address in USA for the period of December 7, 1996 until January 15, 1997 (and perhaps later) is: Dr.Leonid A.Gavrilov, Ph.D. 3 Dalecrest Ct., Apt.102 Timonium MD 21093, USA From owner-ageing@net.bio.net Sat Nov 16 22:00:00 1996 Path: biosci!daresbury!nntp-trd.UNINETT.no!news-stkh.gsl.net!news.gsl.net!news-peer.gsl.net!news.gsl.net!news.sprintlink.net!news-peer.sprintlink.net!uunet!in2.uu.net!netnews.nwnet.net!news-hub.interserv.net!news.interserv.com!news From: phis@sprynet.com (James Howard) Newsgroups: bionet.molbio.ageing Subject: Breast Cancer and Bone Mineral Density Date: Sun, 17 Nov 1996 19:15:56 GMT Organization: InterServ News Service Lines: 56 Message-ID: <56nns3$57r@lal.interserv.com> NNTP-Posting-Host: hd73-042.compuserve.com X-Newsreader: Forte Free Agent 1.0.82 I sent the following to my local newspaper. It is my response to a "Newsday" report by Ridgely Ochs, Nov. 6, that was in my newspaper. I thought this newsgroup might find it interesting. It is about a theory of breast cancer. (For more info on this, find my "theory of cancer" at this newsgroup this summer.) "Study links bone density, breast cancer," page D3, Nov. 6, reported that postmenopausal women "who had the higest bone-mineral density were at 2.0 to 2.5 times the risk of breast cancer compared with women with the lowest bone-mineral." While the investigators who did the study think estrogen is directly involved, they suggest "It could be other hormones." I certainly think other hormones are involved. May 16, 1993, I suggested in the ...News, page 2D, that I think testosterone is rising in this society; March 7, ‘94, I suggested increases in testosterone and low levels of the hormone, DHEA, may cause breast cancer. This is why I think breast cancer is rising so rapidly, and this report of a link between strong bones and breast cancer suppots my idea that an increase in testosterone is definitely linked to the rise in breast cancer. When estrogen is produced by the ovaries, testosterone is also produced. While loss of estrogen is thought to be the cause of osteoporosis, a strong case can be made that it is really loss of testosterone. When female monkeys are given the strong androgen, testosterone, compared to weak androgens, bone-mineral density increases. "We conclude that in the young [female] cynomolgus monkey, long-term androgenic treatment significantly improves some of the mechanical properties of both cortical and trabecular bones, increases bone density, and the stronger the androgen, the more pronounced is the effect" (Bone 1995; 17: 265). In other research, when testosterone is used with estrogen, bone mineral density is increased. "We concluded that in postmenopausal women, treatment with combined estradiol and testosterone implants was more effective in increasing bone mineral density in the hip and lumbar spine than estradiol implants alone." (Maturitas 1995; 21: 227) Women who produce more testosterone have increased bone mineral density. While my idea that testosterone is rising should mean less osteoporosis, a medline search of the literature clearly shows that osteoporosis is actually increasing. Increasing life-span is clearly overwhelming any benefits of increased testosterone in women. The key is that osteoporosis in women is "six-fold that of men;" the increased life-span of women cannot account for this large difference. Men exhibit less osteoporosis, I suggest, because they produce more testosterone. I sent my hypothesis of high testosterone and low DHEA in breast cancer to the Journal of the American Medical Association, Feb 4, ‘94. It was rejected. Later, in 1994, two reports connected high testosterone and low DHEA in breast cancer in women: "Abnormal Production of Androgens in Women with Breast Cancer," Anticancer Res. 1994, 14: 2113 and "Hormonal Profiles in Women with Breast Cancer," Obstet. Gynecol. Clin. North Am. 1994; 21: 751. One known risk factor in breast cancer in women is early menstruation (puberty). This early onset of puberty may also be attributed to the increase in testosterone. My work suggests testosterone is rising in the U.S. I think this increase in testosterone is the cause of the "secular trend," i.e., the increase in size, and earlier puberty, in children. This is why breast cancer may be increasing. I suggest the connection of increased bone density and increased breast cancer in women is due to this increase in testosterone. James Howard From owner-ageing@net.bio.net Sun Nov 17 22:00:00 1996 Path: biosci!ihnp4.ucsd.edu!swrinde!howland.erols.net!news.bbnplanet.com!cam-news-hub1.bbnplanet.com!uunet!in2.uu.net!news-m01.ny.us.ibm.net!news-s01.ny.us.ibm.net!not-for-mail From: "Turner W. Rentz, III" Newsgroups: bionet.molbio.ageing Subject: On the subject of grey hair. Date: Mon, 18 Nov 1996 04:30:29 -0500 Organization: Advanced Technology and Research, Inc. Lines: 24 Message-ID: <32902CB5.189D@ibm.net> Reply-To: treyr@ibm.net NNTP-Posting-Host: slip166-72-134-66.or.us.ibm.net Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 3.0 (Win95; I) Grey hair, actually is regular color it seems, at the root and white at the base. White is a color which occurs from disorganized molecular orienting to reflect several different wavelengths. Toxins have built up to destroy this orientation, the proper stacking of the molecules and poisons that the skin sheds. To lose integrity in this organ is to begin to die. There are too many bugs in the world to survive otherwise. I still cannot fathom the reason why people die and why the toxins cannot be eliminated. Perhaps greying of hair follicles, or exfoliated skin is a clue -- Turner W. Rentz, III Advanced Technology and Research, Inc. http://www.atr.net From owner-ageing@net.bio.net Sun Nov 17 22:00:00 1996 Path: biosci!aol.com!EdKrug From: EdKrug@aol.com Newsgroups: bionet.molbio.ageing Subject: Re: On the subject of grey hair. Date: 18 Nov 1996 12:28:31 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 9 Sender: daemon@net.bio.net Distribution: world Message-ID: <961118141435_1648961685@emout04.mail.aol.com> NNTP-Posting-Host: net.bio.net Toxins?? HA! Aging and death have been around long before we even had fire or language, let alone toxins. The lie is that we are stable an unchanging in absence of outside forces. As soon as we stop growing and expanding we start enter a holding game against entropy. The wonder is that we have accumulated so many diverse mechanisms to retard this decline. Toxins?? HA! Ed Krug, Ph.D., Physiology & Anatomy, BS Physics From owner-ageing@net.bio.net Thu Nov 21 22:00:00 1996 Path: biosci!rutgers!uwm.edu!cs.utexas.edu!natinst.com!news-relay.us.dell.com!swrinde!howland.erols.net!feed1.news.erols.com!uunet!in3.uu.net!netnews.nwnet.net!news-hub.interserv.net!news.sprynet.com!news From: phis@sprynet.com (James Howard) Newsgroups: bionet.molbio.ageing Subject: Breast Cancer Increases: additional information Date: Fri, 22 Nov 1996 10:50:37 GMT Organization: Sprynet News Service Lines: 13 Message-ID: <57404p$ie5@lore.sprynet.com> NNTP-Posting-Host: dd66-163.compuserve.com X-Newsreader: Forte Free Agent 1.0.82 I just found the following citation. It further supports my contention that the increase in breast cancer is the result of increases in testosterone. Berrino F, et al., "Serum Sex Hormone Levels after Menopause and Subsequent Breast Cancer," Journal of the National Cancer Institute 1996; 88: 291 "Conclusions and Implications: This prospective study provides further evidence in support of the already established association between elevated estrogen levels and breast cancer. Even more importantly, it provides new evidence that high serum testosterone levels precede breast cancer occurrence." James Howard From owner-ageing@net.bio.net Sun Nov 24 22:00:00 1996 Path: biosci!bcm.tmc.edu!cs.utexas.edu!howland.erols.net!news.sprintlink.net!news-peer.sprintlink.net!news.mindspring.com!usenet From: lockshin@mindspring.com (Richard A. Lockshin) Newsgroups: bionet.molbio.ageing Subject: NYC Cell Death Dec Meeting, New Announcements Date: Mon, 25 Nov 1996 18:32:21 GMT Organization: MindSpring Enterprises, Inc. Lines: 48 Message-ID: <57cou7$6so@camel0.mindspring.com> Reply-To: lockshin@mindspring.com NNTP-Posting-Host: ip97.an24.new-york4.ny.psi.net X-Server-Date: 25 Nov 1996 18:35:51 GMT X-Newsreader: Forte Free Agent 1.0.82 CELL DEATH SOCIETY (The Death Poets' Society) DECEMBER meeting See below: ================================================== [if duplicated, sorry. The first didn't seem to go through.] NEW PLANS--SEE ALSO NEW PAGES & SITES ADDED TO WEB SITE 11/25/96: We are working to send this by email and announcement on our web page (http://rdz.stjohns.edu/~lockshin/index.html-- check it out and make suggestions) rather than by fax and this route. If you do not receive email announcements and would like them, please reply to this (delete the message) so that we can get your correct address. ===================================================== EVERYONE, PLEASE, SO THAT WE CAN PROVIDE THE MOST EFFICIENT SERVICE PLEASE SEND COMPLETE MAILING ADDRESS, PHONE #, AND FAX #, AND INTEREST. ======================================================= Date: Wednesday, December 4, 1996 Time: 6:00-6:30 PM Pizza, 6:30-8:00 PM Talks & Discussion Place: Rockefeller Univ., 1230 York Ave. Weiss Research Bldg Room 301 Speakers: 1. Yajing Chen (Skirball Institute, NYU Medical Center): A bacterial invasion induces macrophage apoptosis by directly binding to ICE. 2. Timothy Carter (St. John's University): DNA dependent protein kinase and cell death. DRIVING AND ATTENDANCE INSTRUCTIONS Free parking after 5 PM at 66th St. & York Ave. Please car pool since parking space is limited. RSVP: To help us plan for the pizza and the number of attendees, we ask that you call Dr. Zakeri's lab (718-997-3429) and let them know of the number of people coming for the pizza, talk, & if you need parking. RSVP by Tuesday, December 3, 1996 Organizers: Zahra Zakeri, fax 718-997-3445, phone 718-997-3417 Raymond Birge fax 212-327-7943, phone 212-327-7412 SPONSORED BY: Oncor Appligene Cell Death and Differentiation Queens College & Graduate Center of C.U.N.Y. Rockefeller University Richard A. Lockshin (lockshin@mindspring.com;lockshin@sjumusic.stjohns.edu) From owner-ageing@net.bio.net Mon Nov 25 22:00:00 1996 Path: biosci!biosci!not-for-mail From: lockshin@mindspring.com (Richard A. Lockshin) Newsgroups: bionet.celegans,bionet.cellbiol,bionet.drosophila,bionet.general,bionet.immunology,bionet.molbio.ageing,bionet.neuroscience Subject: CELL DEATH SOC 12/4 MEETING, WEB SITE ADDITIONS Date: 26 Nov 1996 11:51:45 -0800 Organization: MindSpring Enterprises, Inc. Lines: 44 Sender: daemon@net.bio.net Distribution: world Message-ID: <57cdah$132@camel2.mindspring.com> Reply-To: lockshin@mindspring.com NNTP-Posting-Host: net.bio.net Xref: biosci bionet.celegans:1169 bionet.cellbiol:6048 bionet.drosophila:2677 bionet.general:24227 bionet.immunology:10342 bionet.molbio.ageing:3064 bionet.neuroscience:16940 CELL DEATH SOCIETY (The Death Poets' Society) November meeting See below: NEW PLANS--SEE ALSO NEW PAGES & SITES ADDED TO WEB SITE 11/25/96: We are working to send this by email and announcement on our web page (http://rdz.stjohns.edu/~lockshin/index.html-- check it out and make suggestions) rather than by fax and this route. If you do not receive email announcements and would like them, please reply to this (delete the message) so that we can get your correct address. PLEASE SEND COMPLETE MAILING ADDRESS, PHONE #, AND FAX #, AND INTEREST. Date: Wednesday, December 4, 1996 Time: 6:00-6:30 PM Pizza, 6:30-8:00 PM Talks & Discussion Place: Rockefeller Univ., 1230 York Ave. Weiss Research Bldg Room 301 Speakers: 1. Yajing Chen (Skirball Institute, NYU Medical Center): A bacterial invasion induces macrophage apoptosis by directly binding to ICE. 2. Timothy Carter (St. John's University): DNA dependent protein kinase and cell death. DRIVING AND ATTENDANCE INSTRUCTIONS Free parking after 5 PM at 66th St. & York Ave. Please car pool since parking space is limited. RSVP: To help us plan for the pizza and the number of attendees, we ask that you call Dr. Zakeri's lab (718-997-3429) and let them know of the number of people coming for the pizza, talk, & if you need parking. RSVP by Wednesday, November 6, 1996 Organizers: Zahra Zakeri, fax 718-997-3445, phone 718-997-3417 Raymond Birge fax 212-327-7943, phone 212-327-7412 SPONSORED BY: Oncor Appligene Cell Death and Differentiation Queens College & Graduate Center of C.U.N.Y. Rockefeller University Richard A. Lockshin (lockshin@mindspring.com;lockshin@sjumusic.stjohns.edu) From owner-ageing@net.bio.net Tue Nov 26 22:00:00 1996 Path: biosci!daresbury!nntp-trd.UNINETT.no!news-stkh.gsl.net!news.gsl.net!eru.mt.luth.se!solace!news.stealth.net!news.idt.net!feed1.news.erols.com!howland.erols.net!news.sprintlink.net!news-peer.sprintlink.net!visi.com!mr.net!news.mid.net!news.uark.edu!news.ualr.edu!news.ach.uams.edu!life.uams.edu!SWBARGER From: swbarger@life.uams.edu Newsgroups: bionet.molbio.ageing Subject: Postdoc opening Date: 27 Nov 1996 22:04:35 GMT Organization: University of Arkansas for Medical Sciences Lines: 24 Message-ID: <57idtj$evt@alvin.ach.uams.edu> Reply-To: swbarger@life.uams.edu NNTP-Posting-Host: life.uams.edu Postdoc Position -- A position is available in a multidisciplinary program aimed at integrating neuropathology of Alzheimer's disease with cell culture analyses of specific molecular events and mechanisms. Specifically, the project will explore role of cytokines such as interleukin-1, S100beta, and secreted APP in generating the neuropathological findings of Alzheimer's. Studies will involve analysis of the interactions between microglia, astrocytes, and neurons in culture. Requirements include a Ph.D. or equivalent and experience with general protein science (SDS-PAGE, immunological techniques) and basic molecular biology. Three years of support are available. Submit curriculum vitae to: Dr. Steven W. Barger Research Service - 151 McClellan VA Medical Center 4300 W. 7th St. Little Rock AR 72205 ph: (501) 661-1202, ext 3796 fax: (501) 671-2524 or -2510 email: swbarger@life.uams.edu